AJ Lanigan: Of Course. Actually, pharma companies are making massive income with therapies like Keytruda and Opdivo that deal with PD-1 and PD-L1. Right here’s the super interesting portion: think about checkpoints as targeted traffic signals. You don’t want an immune process that’s working wild just like a freight prepare waiting for link from Social Bookmarking (2)